Table 1.

Demographic Data.

No. of patients	49 eyes of 45 patients (1 bilateral case)
Sex	29 female (64%), 16 male (36%)
Age, y	Mean 76 (range, 56-90)
Eye	23 right, 23 left, 3 unlisted
Race	All White
Location	All in the United States: 15 Northeast, 9 West, 14 South, 7 Midwest
Autoimmune history  11 (24%) total  4 (13%) excluding hypothyroid	7 hypothyroid 1 uveitis in fellow eye 1 MS 1 Crohn disease 1 inflammatory liver disease
Drug allergies	No pattern (49% had no allergies)
Lens	20 phakic (41%) 29 pseudophakic (59%)
Length of NVAMD diagnosis prior to brolucizumab, mo	4 treatment naive (8%) Mean 34 (range, 0-92)
No. of prior anti-VEGF (before brolucizumab)	Mean 26.4 injections (range, 0-62 injections) Total 1265 injections
Type of injections prior to brolucizumab (in total)	344 (27%) ranibizumab 195 (15%) bevacizumab 726 (57%) aflibercept
Most recent injection prior to brolucizumab	10 ranibizumab (20%) 5 bevacizumab (10%) 29 aflibercept (59%)
Reason to switch to brolucizumab	Extend treatment interval: 32 eyes (65%) Improve efficacy: 29 eyes (59%) Treatment naive: 4 eyes (8%)

Abbreviations: MS, multiple sclerosis; NVAMD, neovascular age-related macular degeneration; VEGF, vascular endothelial growth factor.